Effects of fosfomycin on Shiga toxin-producing Escherichia coli: quantification of copy numbers of Shiga toxin-encoding genes and their expression levels using real-time PCR

References

1. Bennish M. L., Khan W. A., Begum M., Bridges E. A., Ahmed S., Saha D., Salam M. A., Acheson D., Ryan E. T. 2006; Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis 42:356–362 [CrossRef]
   [Google Scholar]
2. Georgopapadakou N. H., Smith S. A., Sykes R. B. 1982; Mode of action of azthreonam. Antimicrob Agents Chemother 21:950–956 [CrossRef]
   [Google Scholar]
3. Horii T., Kobayashi M., Sato K., Ichiyama S., Ohta M. 1998; An in-vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of gram-negative bacilli. J Antimicrob Chemother 41:435–442 [CrossRef]
   [Google Scholar]
4. IDSC 2007 Enterohemorrhagic Escherichia coli Infection in Japan as of April 2007 , Infectious Agents Surveillance Report vol 28 pp 131–132 Infectious Disease Surveillance Center; http://idsc.nih.go.jp/iasr/28/327/tpc327.html
   [Google Scholar]
5. Ichinohe N., Ohara-Nemoto Y., Tajika S., Kaneko M., Tsutsumi R., Takahashi K., Sato S., Ichinohe S., Chida S. 1999; Effects of fosfomycin and norfloxacin on the morphological changes and expression of Shiga-like toxin in enterohemorrhagic Escherichia coli O157 : H7. J Iwate Med Ass 51:557–562 (in Japanese
   [Google Scholar]
6. Ikeda K., Ida O., Kimoto K., Takatorige T., Nakanishi N., Tatara K. 1999; Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157 : H7 infection. Clin Nephrol 52:357–362
   [Google Scholar]
7. Jackson J. J., Kropp H. 1992; β -Lactam antibiotic-induced release of free endotoxin: in vitro comparison of penicillin-binding protein (PBP) 2-specific imipenem and PBP 3-specific ceftazidime. J Infect Dis 165:1033–1041 [CrossRef]
   [Google Scholar]
8. Jackson M. P., Neill R. J., O'Brien A. D., Holmes R. K., Newland J. W. 1987; Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli 933. FEMS Microbiol Lett 44:109–114 [CrossRef]
   [Google Scholar]
9. Kahan F. M., Kahan J. S., Cassidy P. J., Kropp H. 1974; The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 235:364–386 [CrossRef]
   [Google Scholar]
10. Kimmitt P. T., Harwood C. R., Barer M. R. 1999; Induction of type 2 Shiga toxin synthesis in Escherichia coli O157 by 4-quinolones. Lancet 353:1588–1589 [CrossRef]
    [Google Scholar]
11. Kimmitt P. T., Harwood C. R., Barer M. R. 2000; Toxin gene expression by Shiga toxin-producing Escherichia coli : the role of antibiotics and the bacterial SOS response. Emerg Infect Dis 6:458–465 [CrossRef]
    [Google Scholar]
12. Matsushiro A., Sato K., Miyamoto H., Yamamura T., Honda T. 1999; Induction of prophages of enterohemorrhagic Escherichia coli O157 : H7 with norfloxacin. J Bacteriol 181:2257–2260
    [Google Scholar]
13. Ohara-Nemoto Y., Kobayashi M., Kaneko M. 1997; Genotype analysis of enterohemorrhagic Escherichia coli O157 : H7 strains isolated in Iwate prefecture from 1996 to February 1997. Kansenshogaku Zasshi 71:1232–1237 (in Japanese [CrossRef]
    [Google Scholar]
14. Ohara-Nemoto Y., Ikeda Y., Kobayashi M., Sasaki M., Tajika S., Kimura S. 2002; Characterization and molecular cloning of a glutamyl endopeptidase from Staphylococcus epidermidis . Microb Pathog 33:33–41 [CrossRef]
    [Google Scholar]
15. Panos G. Z., Betsi G. I., Falagas M. E. 2006; Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157 : H7 infection?. Aliment Pharmacol Ther 24:731–742 [CrossRef]
    [Google Scholar]
16. Sasaki M., Ohara-Nemoto Y., Tajika S., Kobayashi M., Yamaura C., Kimura S. 2001; Antigenic characterization of a novel Streptococcus anginosus antigen that induces nitric oxide synthesis by murine peritoneal exudates cells. J Med Microbiol 50:952–958
    [Google Scholar]
17. Tarr P. I., Gordon C. A., Chandler W. L. 2005; Shiga-toxin-producing Escherichia coli and haemolytic uremic syndrome. Lancet 365:1073–1086
    [Google Scholar]
18. Tomita T., Ohara-Nemoto Y., Moriyama H., Ozawa A., Takeda Y., Kikuchi K. 2007; A novel in vitro pharmacokinetic/pharmacodynamic model based on two-compartment open model used to simulate serum drug concentration-time profiles. Microbiol Immunol 51:567–575 [CrossRef]
    [Google Scholar]
19. Wong C. S., Jelacic S., Harbeeb R. L., Watkins S. L., Tarr P. I. 2000; The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157 : H7 infections. N Engl J Med 342:1930–1936 [CrossRef]
    [Google Scholar]
20. Zhang X., McDaniel A. D., Wolf L. E., Keusch G. T., Waldor M. K., Acheson D. W. K. 2000; Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 181:664–670 [CrossRef]
    [Google Scholar]